Jaran Eriksen

I am an infectious diseases physician and clinical pharmacologist currently working at Stockholm South General Hospital, where I devote half of my time to work in our HIV clinic. I am also an Associate professor at Karolinska Institutet, where I am the group leader of the research group "Infektion Venhälsan" at the Department of Clinical Science and Education (KISÖS). In addition, I am affiliated to the Karolinska Institutet Department of Global Public Health (GPH) where I am member of the Health Systems and Policy Research group/Improving Use of Medicines team. I am currently also co-lead of the working group for GlobeLife, an initiative aiming to promote and facilitate global health research and training collaboration between Karolinska Institutet and Uppsala University. I am a member of the Swedish National Reference group for Antiviral Therapy (RAV) and part of the group developing and updating the national guidelines for HIV treatment and prevention.

Qualifications
2021: Docent (Associate professor) in Global Health
2006: PhD Karolinska Institutet: Managing childhood malaria in rural Tanzania
- focusing on drug use and resistance
2001: MD Karolinska Institutet

Clinical specialist certification
2022 specialist physician in infectious diseases.
2016 specialist physician in clinical pharmacology.

Current position
Specialist physician in infectious diseases, Unit of Infectious
diseases/Venhälsan, Södersjukhuset, Stockholm, 40% research time

My research focuses on different aspects of rational use of medicines, regarding management of infectious diseases common in low-and middle-income countries (LMIC). Within this field my interest spans broadly from behavioural change and policy to pharmacokinetics and resistance mutations. Although my focus is on LMIC, I also work in high-income settings, such as Sweden. I aim to develop models for improving treatment of infectious diseases that can be applied in both low- and high-resource settings. A major part of my work has a health systems approach but also includes clinical trials with pharmacokinetic and pharmacogenetic aspects and how these influence treatment outcome and practices.